Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F21%3A00074426" target="_blank" >RIV/65269705:_____/21:00074426 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00209805:_____/21:00078675 RIV/00216224:14110/21:00121472

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S1877782121000461" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1877782121000461</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.canep.2021.101929" target="_blank" >10.1016/j.canep.2021.101929</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients

Popis výsledku v původním jazyce

Background: Numbers of patients who develop subsequent primary tumours have markedly increased recently. This study aimed to carry out a comprehensive analysis documenting the risk of incidence of subsequent haematological malignancies. Methods: The Czech National Cancer Registry was the main data source, containing records of 126,822 haematological malignancies diagnosed in the period 1977-2016. Subsequent haematological malignancies were identified according to IACR rules. Joinpoint regression was employed to assess the time trends. The risk of development of subsequent haematological malignancy was evaluated by the standardised incidence ratio. The Kaplan-Meier curves were used to assess the differences in survival. Results: Age-standardised incidence of subsequent haematological malignancies increased from 0.5 in 1977 to 9.1 in 2016. In 1992, there was a significant change in the trend: a sharp increase by 7.7 % annually was revealed thereafter. The risk of development of a haematological malignancy was approximately 1.5 times higher in persons with history of any cancer than in the general Czech population. Patients with haematological malignancies-mainly myelodysplastic syndromes, polycythaemia vera and non-Hodgkin lymphoma-were shown to be at the highest risk of developing a subsequent haematological malignancy. While the median survival following a first haematological malignancy was 2.3 years, it was only 1.1 years for subsequent haematological malignancies (p &lt; 0.001). Conclusions: Our study identified the highest-risk diagnoses in terms of development of subsequent haematological malignancy. The results might be useful to set up correctly follow-up procedures from which cancer patients could benefit.

Název v anglickém jazyce

Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients

Popis výsledku anglicky

Background: Numbers of patients who develop subsequent primary tumours have markedly increased recently. This study aimed to carry out a comprehensive analysis documenting the risk of incidence of subsequent haematological malignancies. Methods: The Czech National Cancer Registry was the main data source, containing records of 126,822 haematological malignancies diagnosed in the period 1977-2016. Subsequent haematological malignancies were identified according to IACR rules. Joinpoint regression was employed to assess the time trends. The risk of development of subsequent haematological malignancy was evaluated by the standardised incidence ratio. The Kaplan-Meier curves were used to assess the differences in survival. Results: Age-standardised incidence of subsequent haematological malignancies increased from 0.5 in 1977 to 9.1 in 2016. In 1992, there was a significant change in the trend: a sharp increase by 7.7 % annually was revealed thereafter. The risk of development of a haematological malignancy was approximately 1.5 times higher in persons with history of any cancer than in the general Czech population. Patients with haematological malignancies-mainly myelodysplastic syndromes, polycythaemia vera and non-Hodgkin lymphoma-were shown to be at the highest risk of developing a subsequent haematological malignancy. While the median survival following a first haematological malignancy was 2.3 years, it was only 1.1 years for subsequent haematological malignancies (p &lt; 0.001). Conclusions: Our study identified the highest-risk diagnoses in terms of development of subsequent haematological malignancy. The results might be useful to set up correctly follow-up procedures from which cancer patients could benefit.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cancer Epidemiology

ISSN

1877-7821

e-ISSN

—

Svazek periodika

72

Číslo periodika v rámci svazku

JUN

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

101929

Kód UT WoS článku

000652749700004

EID výsledku v databázi Scopus

2-s2.0-85103668664